Publication number: 20240239788
Abstract: Compounds or their pharmaceutically acceptable salts can inhibit the G12D mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
Type:
Application
Filed:
April 15, 2022
Publication date:
July 18, 2024
Inventors:
David L. Sloman, Gianni Chessari, Patrick Schöpf, Steven Howard, Yuichi Kawai, Kazuaki Shibata, Hiroki Asakura, Takao Uno, Takeshi Sagara, Masayuki Nakamura, Yu Kobayakawa, David Jonathan Bennett, Indu Bharathan, Thomas H. Graham, Yongxin Han, Zahid Hussain, Xiaoshen Ma, Mihir Mandal, Ryan D. Otte, Anandan Palani, Uma Swaminathan, Mycah Uehling, Yingchun Ye, Ryan Chau, Alec H. Christian, Symon Gathiaka, Timothy J. Henderson, Elisabeth T. Hennessy, Andrew J. Hoover, Shuhei Kawamura, Igri Kolaj, Thomas W. Lyons, Matthew J. Mitcheltree, Aaron Sather
Publication number: 20230322785
Abstract: The present invention provides compounds of the structural Formula (I) and pharmaceutically acceptable salts thereof, wherein, are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.
Type:
Application
Filed:
July 21, 2022
Publication date:
October 12, 2023
Applicant:
Merck Sharp & Dohme LLC
Inventors:
Amjad Ali, Christopher W. Boyce, Jared N. Cumming, Duane DeMong, Thomas H. Graham, Subrahmanyam Gudipati, Andrew J. Hoover, Xianhai Huang, Rongze Kuang, Jae-Hun Kim, Joseph M. Kelly, Yeon-Hee Lim, Michael Man-Chu Lo, Jesus Moreno, Jing Su, Heping Wu, Dong Xiao, Younong Yu, Xiaohong Zhu
Publication number: 20220220117
Abstract: In its many embodiments, the present invention provides certain 9-substituted amino triazolo quinazoline compounds of the structural Formula (I): and pharmaceutically acceptable salts thereof, wherein, ring A, R1 and R2 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.
Type:
Application
Filed:
March 31, 2022
Publication date:
July 14, 2022
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
Matthew A. Larsen, Amjad Ali, Jared Cumming, Duane DeMong, Qiaolin Deng, Thomas H. Graham, Elisabeth Hennessy, Andrew J. Hoover, Ping Liu, Kun Liu, Umar Faruk Mansoor, Jianping Pan, Christopher W. Plummer, Aaron Sather, Uma Swaminathan, Huijun Wang, Yonglian Zhang
Publication number: 20210107904
Abstract: In its many embodiments, the present invention provides certain 9-substituted amino triazolo quinazoline compounds of the structural Formula (I): and pharmaceutically acceptable salts thereof, wherein, ring A, R1 and R2 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.
Type:
Application
Filed:
November 26, 2019
Publication date:
April 15, 2021
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
Matthew A. Larsen, Amjad Ali, Jared Cumming, Duane DeMong, Qiaolin Deng, Thomas H. Graham, Elisabeth Hennessy, Andrew J. Hoover, Ping Liu, Kun Liu, Umar Faruk Mansoor, Jianping Pan, Christopher W. Plummer, Aaron Sather, Uma Swaminathan, Huijun Wang, Yonglian Zhang